Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from the immune system. The research, published in Cancer Cell in September, could lead to a new therapeutic option for patients with these types of tumors. Advanced bladder cancer is aggressive and patients generally have poor prognoses. Several immune checkpoint inhibitors have been approved by the Food and Drug Administration for bladder cancer, but they only sustain good responses in about 20 percent of patients. When people get cancer, a type of immune cell called a "natural killer cell" swings into action to try